Nabsys and Indiana University entered a research partnership that will use Nabsys’ OhmX platform for electronic genome mapping in blood cancer research. The collaboration will be led by Kevin Booth at the IU School of Medicine, with initial focus areas including acute myeloid leukemia and myelodysplastic syndromes. Electronic genome mapping aims to provide high-resolution structural variant characterization without relying solely on traditional sequencing workflows. For labs, that could translate into more actionable genomic insights for hematologic malignancies where complex rearrangements and therapy resistance patterns matter. The partnership matters because it brings a next-generation mapping platform into a disease-focused academic setting, potentially accelerating proof-of-feasibility for clinically relevant biomarker discovery.